The North America Digital PCR Market is poised for robust growth, driven by technological advancements and increasing demand for precise genetic analysis. It was valued at USD 380 million in 2025 and is projected to reach USD 1,020 million by 2035, expanding at a CAGR of 9.5% during 2024-2035.
The economic impact of tariffs on "North America Digital PCR Market".
Market Growth Drivers
Rising prevalence of infectious and chronic diseases such as cancer and COVID-19 is boosting the adoption of digital PCR (dPCR) due to its enhanced sensitivity and accuracy. Companies like Bio-Rad Laboratories have experienced increased demand for dPCR solutions for early disease detection and quantification of low-level pathogens, strengthening their market position.
Technological advancements in digital PCR platforms, including improved multiplexing and integration with cloud-based data management, are driving market growth. For example, Thermo Fisher Scientific introduced new high-throughput dPCR instruments in early 2024, enabling researchers and clinicians to analyze a greater number of samples with improved precision and efficiency.
Market Trends
Expansion of applications in precision medicine: Digital PCR is being increasingly utilized in precision oncology, prenatal testing, and rare mutation detection. Leading players like QIAGEN have rolled out application-specific dPCR assays, catering to personalized medicine and tailored therapy decisions, as observed in their 2024 North American product launches.
Integration of digital PCR with next-generation sequencing (NGS) workflows: Recent collaborations, such as Bio-Rad's partnership with Illumina announced in March 2024, focus on combining dPCR’s absolute quantification and NGS’s comprehensive sequencing, enabling comprehensive and optimized biomarker discovery, particularly in cancer and infectious diseases.
Market Opportunities
The growing adoption of digital PCR in clinical diagnostics, especially for liquid biopsy and non-invasive prenatal testing, presents significant market expansion opportunities. Danaher Corporation is investing in expanding its service offerings to capitalize on this demand and broaden its market footprint.
Rising government and private funding for genomic research, coupled with the establishment of advanced molecular diagnostics infrastructure in North America, is creating lucrative opportunities for market players to introduce innovative dPCR solutions and expand collaborations with academic institutes.
North America Digital PCR Market Revenue (USD Million), 2020-2035
The chart depicts a strong upward trend in market revenue from USD 210 million in 2020 to USD 1,020 million in 2035. Early years (2020-2024) show moderate growth buoyed by initial technology adoption, followed by accelerated expansion (2025-2035) as clinical applications proliferate and industrial uptake increases. Technological innovations, rising disease prevalence, and expanding research applications are key contributors to sustained revenue growth across the forecast period.
North America Digital PCR Market by Regions Share (%), 2025
In 2025, the United States clearly dominates the North America Digital PCR market, accounting for 78% of total market share, owing to its advanced healthcare infrastructure and robust investment in molecular diagnostics. Canada follows as the second-largest market with 16%, supported by increasing adoption in clinical and research settings. Mexico and other North American regions collectively hold the remaining 6%, highlighting the region’s growing but comparatively smaller engagement in digital PCR technologies.
Recent Developments in North America Digital PCR Market (Last 6 Months)
In May 2024, Thermo Fisher Scientific launched the QuantStudio Absolute Q dPCR System in North America, introducing a fully integrated and automated solution with a compact footprint and enhanced data analysis capabilities. This launch is expected to streamline workflows for clinical and research laboratories, further expanding Thermo Fisher Scientific’s market share.
In April 2024, Bio-Rad Laboratories announced the U.S. FDA approval of its Droplet Digital PCR (ddPCR) SARS-CoV-2 Kit, allowing for its clinical use. This regulatory milestone not only broadens the adoption of dPCR in infectious disease diagnostics but also underscores Bio-Rad’s leadership in the evolving molecular diagnostics market.
In February 2024, QIAGEN entered into a strategic partnership with the University of California, San Diego, to co-develop digital PCR assays for rare genetic disorder detection. This collaboration aims to accelerate the translation of dPCR-based research into clinical practice and expand the real-world utility of QIAGEN’s dPCR portfolio.
Press Releases